Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab905
In this investigation, upadacitinib showed comparable efficacy as monotherapy and in combination with nbDMARDs in PsA. In coming to this conclusion investigators aimed to assess the efficacy and safety of upadacitinib as monotherapy or in combination with nbDMARDs in patients with PsA.
To achieve this aim patients were randomised (UPA 15mg, 30mg QD, placebo or Adulimumab) and treated for 24 weeks. Patients were classed as receiving monotherapy if they received UPA alone or combination therapy if they received background treatment with one or two nbDMARDs.
Additional conclusions also included the safety profile of upadacitinib. Demonstrating generally similar safety when used as monotherapy and combination therapy. Hepatic disorder events and creatine phosphokinase elevation were less common with monotherapy vs combination therapy.